Image Source : MediCircle
Emcure Pharmaceuticals Ltd and Sanofi India Ltd have announced an exclusive distribution and promotion agreement for Sanofi’s oral anti-diabetic (OAD) drugs in India. The partnership aims to enhance nationwide access to trusted diabetes therapies, effective immediately.
Key Highlights:
- Emcure will distribute and promote Sanofi’s leading OAD brands, including Amaryl and Cetapin
- Sanofi retains ownership and manufacturing responsibilities for the products
- The collaboration leverages Emcure’s deep distribution network across urban and rural India
Market Context:
- Over 100 million Indians live with type 2 diabetes, with more than 60% having uncontrolled blood sugar levels
- The alliance is expected to improve patient outcomes by expanding reach to underserved regions
- No employee transfers will occur between the companies as part of this deal
Leadership Commentary:
- Sanofi emphasized unlocking the full potential of its OAD portfolio
- Emcure highlighted the synergy with its existing diabetes care offerings
Sources: Business Upturn, Economic Times, Sanofi India Press Releases.
Advertisement
Advertisement